More exciting press coverage following $153 Million financing - Series C

Please click on the links for full coverage updates

ENDPOINTSNEWS	Novartis partner Artios bags mega-round to drive clinical work on DNA damage repair factors
Fierce Biotech	Artios raises $153M to fund DNA damage repair clinical trials
Business Leader	ARTIOS ANNOUNCES £110M SERIES C FINANCING LED BY OMEGA FUNDS AND TCG X
Private Equity Wire	Arix Bioscience-backed Artios secures USD153m in Series C financing led by Omega Funds and TCG X
MedNous	Artios raises $153 million in Series C financing
BioSpace	Artios Adds $153M to the Bank Amidst a Year of Major Collab Deals
First Word PHARMA	Artios Announces $153 Million (£110 Million) Series C Financing Led by Omega Funds and TCG X
BioWorld	Artios’ $153M series C to expand DDR platform beyond synthetic lethality
European Biotechnology	Artios Pharma Ltd raises US-$153m Series C financing
Precision Oncology News	Artios Pharma Raises $153M in Series C Funding
PitchBook	UK’s Artios Pharma lands $153M Series C
BIOCENTURY	Quick Takes: Three times and it’s still charming for AbbVie, Calico
BUSINESSWEEKLY	US investors lead $153m round for Artios Pharma
Cambridge Independent	Artios Pharma secures £110m Series C financing to progress its cancer-killing DDR platform
Scrip-Informa Pharma Intelligence	Artios Banks $153m On The Back Of Novartis And Merck KGaA Deals
LABIOTECH.EU	Artios’ €129M Series C Pushes Limits of DNA Repair in Cancer